The same authors have demonstrated that in vitro treatment with the specific c-MET tyrosine kinase inhibitor PHA665752, induced apoptosis of DLBCL cells through inhibition of the PI3K/AKT pathway: based on these observations they suggested that c-MET targeting may thus represent a valuable therapy for DLBCL [37]. This evidence concerns the gene MET and diffuse large B-cell lymphoma.